Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAPNASDAQ:CRVONASDAQ:ELEVNASDAQ:IGMS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.27-3.3%$0.26$0.20▼$1.48$70.90M2.861.82 million shs257,528 shsCRVOCervoMed$7.87-1.1%$9.18$1.80▼$22.57$68.49M-0.231.34 million shs112,910 shsELEVElevation Oncology$0.30-1.0%$0.31$0.22▼$4.33$17.92M1.591.38 million shs467,202 shsIGMSIGM Biosciences$1.24+1.6%$1.22$0.92▼$22.50$74.12M0.61310,811 shs74,196 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-3.28%-1.42%-2.17%-50.81%-73.93%CRVOCervoMed-1.13%-7.52%-13.99%+256.11%-56.81%ELEVElevation Oncology-0.98%-4.54%-15.03%-41.27%-92.10%IGMSIGM Biosciences+1.64%+5.08%-4.62%-7.46%-86.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.7373 of 5 stars4.23.00.00.03.20.80.0CRVOCervoMed3.389 of 5 stars4.43.00.00.02.91.70.6ELEVElevation Oncology2.6257 of 5 stars4.22.00.00.01.91.70.6IGMSIGM Biosciences3.9554 of 5 stars3.01.00.04.62.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.43Hold$1.52460.06% UpsideCRVOCervoMed 2.89Moderate Buy$27.63251.02% UpsideELEVElevation Oncology 2.30Hold$3.391,019.24% UpsideIGMSIGM Biosciences 1.90Reduce$5.50343.55% UpsideCurrent Analyst Ratings BreakdownLatest ELEV, IGMS, CRVO, and ADAP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.465/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.004/11/2025ADAPAdaptimmune TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/26/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.753/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.50(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$179.64M0.39N/AN/A$0.17 per share1.59CRVOCervoMed$7.14M9.59N/AN/A$1.30 per share6.05ELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AIGMSIGM Biosciences$2.68M27.65N/AN/A$3.46 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$113.87M-$0.27N/AN/AN/A-25.43%-74.15%-15.09%8/11/2025 (Estimated)CRVOCervoMed-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)ELEVElevation Oncology-$45.70M-$0.82N/AN/AN/AN/A-59.73%-40.05%8/5/2025 (Estimated)IGMSIGM Biosciences-$246.42M-$3.27N/AN/AN/A-7,534.03%-155.42%-61.04%8/13/2025 (Estimated)Latest ELEV, IGMS, CRVO, and ADAP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ELEVElevation Oncology-$0.20-$0.24-$0.04-$0.24N/AN/A5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/13/2025Q1 2025IGMSIGM Biosciences-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million3/24/2025Q4 2024ADAPAdaptimmune Therapeutics-$0.17-$0.26-$0.09-$0.29$16.56 million$3.22 million3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 million3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/A3/6/2025Q4 2024IGMSIGM Biosciences-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics0.623.853.82CRVOCervoMedN/A15.0415.04ELEVElevation Oncology0.4517.7717.77IGMSIGM BiosciencesN/A5.225.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%CRVOCervoMed25.15%ELEVElevation Oncology83.70%IGMSIGM Biosciences42.79%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%CRVOCervoMed35.40%ELEVElevation Oncology8.10%IGMSIGM Biosciences57.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490261.52 million224.05 millionOptionableCRVOCervoMed48.70 million3.93 millionNot OptionableELEVElevation Oncology4059.22 million54.33 millionOptionableIGMSIGM Biosciences19059.78 million25.57 millionOptionableELEV, IGMS, CRVO, and ADAP HeadlinesRecent News About These CompaniesIGM Biosciences earnings missed by $0.51, revenue fell short of estimatesMay 24, 2025 | investing.comSanofi Purchases New Shares in IGM Biosciences, Inc. (NASDAQ:IGMS)May 19, 2025 | marketbeat.comIGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comIGM Biosciences ends agreement with SanofiMay 10, 2025 | investing.comIGM Biosciences says it is dropping development of imvotamabMay 10, 2025 | thepharmaletter.comIGM Biosciences (IGMS) to Release Earnings on WednesdayMay 9, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 445,260 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS)May 4, 2025 | marketbeat.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 1.5% - Should You Sell?May 1, 2025 | marketbeat.comWhy IGM Biosciences, Inc.’s (IGMS) Stock Is Down 6.85%April 24, 2025 | aaii.comWhy IGM Biosciences, Inc.’s (IGMS) Stock Is Down 5.91%April 17, 2025 | aaii.comBank of America Securities downgrades IGM Biosciences (IGMS) to a SellApril 9, 2025 | markets.businessinsider.comIGM Biosciences (IGMS) Gets a Hold from RBC CapitalMarch 7, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Sell Rating for IGM Biosciences (IGMS)March 7, 2025 | markets.businessinsider.comIGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 27, 2025 | zacks.comIgm BiosciencesFebruary 16, 2025 | forbes.comIGM Biosciences (IGMS) Receives a Hold from Bank of America SecuritiesFebruary 13, 2025 | markets.businessinsider.comDown -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a TurnaroundFebruary 5, 2025 | zacks.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMSFebruary 1, 2025 | accessnewswire.comIGM Biosciences stock plunges to 52-week low of $1.59January 28, 2025 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMSJanuary 28, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMSJanuary 26, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodRecession Prep: Consumer Staples are BackBy Jeffrey Neal Johnson | May 5, 2025View Recession Prep: Consumer Staples are BackD-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?By Nathan Reiff | May 28, 2025View D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay?ELEV, IGMS, CRVO, and ADAP Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.27 -0.01 (-3.28%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.28 +0.01 (+4.02%) As of 05/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.CervoMed NASDAQ:CRVO$7.87 -0.09 (-1.13%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$7.66 -0.22 (-2.73%) As of 05/28/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Elevation Oncology NASDAQ:ELEV$0.30 0.00 (-0.98%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.32 +0.02 (+6.12%) As of 05/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.IGM Biosciences NASDAQ:IGMS$1.24 +0.02 (+1.64%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.24 0.00 (0.00%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
